Jade Biosciences Stock (NASDAQ:JBIO)


FinancialsChart

Previous Close

$8.29

52W Range

$6.57 - $105.00

50D Avg

$32.03

200D Avg

$71.25

Market Cap

$8.67M

Avg Vol (3M)

$190.69K

Beta

0.92

Div Yield

$2.40 (25.50%)

JBIO Company Profile


Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

50

IPO Date

Apr 29, 2025

Website

JBIO Performance


JBIO Financial Summary


Dec 24
Revenue-
Operating Income$-71.08K
Net Income$-93.96K
EBITDA-
Basic EPS$-18.79
Diluted EPS$-18.79

Fiscal year ends in Dec 24 | Currency in USD